Background: International guidelines in asthma and allergy has been updated for COVID-19 pandemic and pandemic has caused dramatic changes in allergy and immunology services. However, it is not known whether specialty-specific recommendations for COVID-19 are followed by allergists. Objectives: By conducting this study, we aimed to determine the attitudes and experiences of adult/pediatric allergists on allergy management during COVID-19. Method: We used a 20-question survey to elicit data from allergists (residents and pediatric and adult allergists registered to the Turkish National Society of Allergy and Clinical Immunology) across Turkey via e-mail. We analyzed the data statistically for frequency distributions and descriptive analysis. Results: A total of 183 allergists participated in the survey. Telemedicine was used for management of asthma (73%), allergic rhinitis (53%), atopic dermatitis (51%), chronic urticaria/angioedema (59%), drug hypersensitivity (45%), food allergy (48%), venom allergy (30%), anaphylaxis (22%), and hereditary angioedema (28%). Thirty-one percent of the respondents discontinued subcutaneous immunotherapy (SCIT) during the COVID-19 pandemic. Thirty-four percent of the physicians reported interruption of systemic steroid use in asthma patients, and 25% of the respondents discontinued biological therapy. Conclusions: Allergists in Turkey have been using telemedicine at a high rate during the COVID-19 pandemic for asthma and rhinitis. The continuation rate of SCIT was low while the discontinuation rate of biologicals and systemic steroid use in asthma was high in Turkey. Our study results and learning from the experiences of other countries and specialties may help to optimize allergy practice and compatibility with international guidelines.

1.
World Allergy organization (WAO)
. https://www.worldallergy.org/COVID-19 Information;
2020
. Accessed June 27, 2020.
2.
GINA guidelines. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Revised asthma guidelines
2020
. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed March 19, 2020.
3.
NICE COVID-19 rapid guideline: severe asthma. https://www.guidelines.co.uk/covid-19-rapid-guideline-severe-asthma/455275.article. Accessed April 17, 2020.
4.
National Society of Allergy and Clinical Immunology (TNSACI)
. https://www.aid.org.tr/
5.
Bousquet
J
,
Jutel
M
,
Akdis
CA
,
Klimek
L
,
Pfaar
O
,
Nadeau
KC
, et al.
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
.
[published online ahead of print, 2020 Jun 26]
.
Allergy
.
2020
Jun
;
all.14471
.
[PubMed]
0105-4538
6.
Gisondi
P
,
Piaserico
S
,
Conti
A
,
Naldi
L
.
Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice
.
J Eur Acad Dermatol Venereol
.
2020
Jun
;
34
(
6
):
1196
201
.
[PubMed]
0926-9959
7.
Muddasani
S
,
Housholder
A
,
Fleischer
AB
.
An assessment of United States dermatology practices during the COVID-19 outbreak
.
J Dermatolog Treat
.
2020
Aug
;
31
(
5
):
436
8
.
[PubMed]
0954-6634
8.
Cai
K
,
He
J
,
Wong
PK
,
Manolios
N
.
The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia
.
Eur J Rheumatol
.
2020
Aug
;
7
Suppl 2
:
S91
3
. ;
Epub ahead of print
.
[PubMed]
2147-9720
9.
Klimek
L
,
Jutel
M
,
Akdis
C
,
Bousquet
J
,
Akdis
M
,
Bachert
C
, et al.;
ARIA-MASK Study Group
.
Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement
.
Allergy
.
2020
Jul
;
75
(
7
):
1546
54
.
[PubMed]
0105-4538
10.
Vultaggio
A
,
Agache
I
,
Akdis
CA
,
Akdis
M
,
Bavbek
S
,
Bossios
A
, et al.
Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement
.
[published online ahead of print, 2020 Jun 5]
.
Allergy
.
2020
Jun
;
all.14407
.
[PubMed]
0105-4538
11.
Shaker
MS
,
Oppenheimer
J
,
Grayson
M
,
Stukus
D
,
Hartog
N
,
Hsieh
EW
, et al.
COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic
.
J Allergy Clin Immunol Pract
.
2020
May
;
8
(
5
):
1477
1488.e5
.
[PubMed]
2213-2198
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.